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rapid communications

A Phase I First-in-Human Study of
ABBV-383, a B-Cell Maturation Antigen 3 CD3
Bispeciﬁc T-Cell Redirecting Antibody, in
Patients With Relapsed/Refractory
Multiple Myeloma
Anita D’Souza, MD1; Nina Shah, MD2; Cesar Rodriguez, MD3; Peter M. Voorhees, MD4; Katja Weisel, MD5; Orlando F. Bueno, MD, PhD6;
Rajvineeth K. Pothacamury, MD6; Kevin J. Freise, PhD6; Susan Yue, MD6; Jeremy A. Ross, PhD6; Akshanth R. Polepally, PhD6;
Chetasi Talati, MD6; Shane Lee, MS6; Ziyi Jin, MS6; Ben Buelow, MD, PhD7; Ravi Vij, MD8; and Shaji Kumar, MD9

abstract

PURPOSE ABBV-383, a B-cell maturation antigen 3 CD3 T-cell engaging bispeciﬁc antibody, has demonstrated
promising results in an ongoing ﬁrst-in-human phase I study (ClinicalTrials.gov identiﬁer: NCT03933735) in
patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efﬁcacy outcomes of
this phase I dose escalation/expansion study.
METHODS Patients with RRMM ($ three prior lines including a proteasome inhibitor, an immunomodulatory
drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2
hours once every 3 weeks, without any step dosing. A 3 1 3 design with backﬁlling for dose escalation was used
(intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion.
RESULTS As of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n 5 73; dose expansion [60
mg], n 5 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common
hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia
(29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%).
Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all
efﬁcacy-evaluable patients (n 5 122; all doses), the objective response rate (ORR) was 57% and very good
partial response (VGPR) or better ($ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n 5 49), the
ORR and $ VGPR rates were 59% and 39%, respectively; and in the $ 40 mg dose escalation plus dose
expansion cohorts (n 5 79) were 68% and 54%, respectively.
CONCLUSION ABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses $ 40 mg. This novel
therapy’s promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation.
J Clin Oncol 40:3576-3586. © 2022 by American Society of Clinical Oncology
Creative Commons Attribution Non-Commercial No Derivatives 4.0 License
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Multiple myeloma (MM) is the second most prevalent
hematologic malignancy globally.1 Treatment options
for MM have improved substantially over the past
20 years, with many new drug classes, such as
proteasome inhibitors (PIs), immunomodulatory drugs
(IMiDs), and monoclonal antibodies (mAbs), being
introduced that have increased life expectancy.2 Despite these advances, patients will ultimately develop
drug-resistant disease and progress to relapsed/
refractory multiple myeloma (RRMM). Thus, patients
with RRMM represent a signiﬁcant treatment challenge, as they have a poor prognosis.3
Survival is limited in patients with RRMM with a median
overall survival (OS) of 5.6-11.2 months in patients

refractory to CD38-targeted mAbs4 and a median OS of
5.1-11.5 months in patients who are double or triple/
quadruple refractory to PIs and IMiDs.3,5 Drug resistance, which represents an important challenge for the
treatment of RRMM, is due to a number of possible
mechanisms including changes in the tumor microenvironment, clonal evolution, P-glycoprotein overexpression in MM cells, and multidrug resistance gene
polymorphism.6 Therefore, there is still a need to develop new therapies with novel mechanisms of action to
target RRMM cells effectively and improve treatment
outcomes and overall quality of life for patients.
B-cell maturation antigen (BCMA), also known as
tumor necrosis factor receptor superfamily member 17
or CD269, is a type III transmembrane glycoprotein
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CONTEXT
Key Objective
There remains an unmet clinical need for novel therapies that can overcome treatment resistance and improve overall
outcomes for patients with relapsed/refractory multiple myeloma. B-cell maturation antigen has emerged as a promising
therapeutic target in multiple myeloma. This trial describes outcomes with ABBV-383, an anti B-cell maturation
antigen 3 CD3 bispeciﬁc monoclonal antibody in patients with relapsed/refractory multiple myeloma ($ three prior lines
of therapy: proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody).
Knowledge Generated
ABBV-383 was well tolerated in the overall population (N 5 124), with cytokine release syndrome (57%) the most common
treatment-emergent adverse event; majority of events were grades 1/2 (55%). An objective response rate of 68%
and $ very good partial response rate of 54% were reported at the therapeutic doses of $ 40 mg. Median duration of
response and progression-free survival were not reached (median follow-up: 10.8 months).
Relevance
The promising preliminary antitumor activity in heavily pretreated patients supports further exploration of ABBV-383 in
patients with multiple myeloma in larger clinical trials.

that is highly expressed on MM cells, but not on other normal
tissues aside from normal plasma cells.7,8 BCMA is involved
in the regulation of B-cell proliferation, survival, maturation,
and differentiation into plasma cells.7 Thus, BCMA has
emerged as a novel treatment target for MM because of its
highly selective expression on malignant plasma cells.8,9 A
number of BCMA-targeted therapies are being developed,
including chimeric antigen receptor–modiﬁed T-cell (CAR-T)
therapies, antibody-drug conjugates (ADCs), and T-cell
engaging bispeciﬁc mAbs (T-BsAbs),7-9 and some have
received approval (accelerated and/or full approval) by the
US Food and Drug Administration and the European
Medicines Agency. Approved agents include belantamab
mafodotin (ﬁrst-in-class anti-BCMA immunoglobulin [Ig]G1
ADC), idecabtagene vicleucel, and ciltacabtagene autoleucel (BCMA-targeted CAR-T therapies).10-15
ABBV-383 (formerly known as TNB-383B), is a nextgeneration, fully human, monoclonal, IgG4 T-BsAb,
BCMA-targeted therapy, which incorporates a lowactivating CD3 that preclinically decouples T-cell activation from cytokine release and preferentially activates effector over regulatory T cells.16-18 ABBV-383 consists of two
heavy chains and one light chain: heavy chain 1 and the
kappa light chain form the antigen-binding site that recognizes and binds to human CD3 with low afﬁnity (1.3 mM),
whereas heavy chain 2 targets BCMA with high afﬁnity and
avidity.16,18 The unique design of ABBV-383 maximizes
MM target-cell killing while potentially minimizing off-target
toxicity and cytokine release, as demonstrated in preclinical
studies. These results may translate to the improved tolerability and efﬁcacy in vivo.18 ABBV-383 has demonstrated antitumor cell activity with minimal cytokine release
in preclinical studies.16,17 Ex vivo efﬁcacy was also demonstrated against bone marrow mononuclear cells freshly
isolated from patients with relapsed MM, with only a mild

increase of cytokines associated with cytokine release
syndrome (CRS).18
Herein, we report interim results from the ﬁrst-in-human
phase I trial that is currently ongoing to investigate the
safety, clinical pharmacology, and clinical activity of ABBV383 in patients with RRMM.
METHODS
Study Design
To our knowledge, this study was the ﬁrst-in-human, phase I,
multicenter, open-label clinical trial of ABBV-383 that
consisted of a dose escalation phase followed by doseexpansion phase. The primary objectives of the study
evaluated the safety and tolerability, determined the maximum tolerated dose (MTD) or recommended phase II dose,
and evaluated clinical pharmacology of ABBV-383 monotherapy. The secondary objective evaluated the clinical
activity of ABBV-383 monotherapy according to the 2016
International Myeloma Working Group (IMWG) criteria.19
All patients provided written informed consent before study
entry. The study was approved by the relevant institutional
review boards and/or independent ethics committees, and
was conducted according to the International Conference
on Harmonisation Good Clinical Practice guidelines and the
Declaration of Helsinki. This study is registered with ClinicalTrials.gov (identiﬁer: NCT03933735).
Patient Eligibility
Full eligibility criteria are listed in the Appendix Table A1
(online only). Brieﬂy, patients (age $ 18 years) with RRMM
($ three prior lines of therapy that included a PI, an IMiD,
and an anti-CD38 mAb), estimated glomerular ﬁltration
rate $ 30 mL/min as calculated by the Modiﬁcation of Diet in
Renal Disease formula, and Eastern Cooperative Oncology
Group performance status (ECOG PS) score # 2 were
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enrolled. Prior treatment with a BCMA-targeted therapy was
prohibited, and patients were not candidates for treatment
regimens known to provide clinical beneﬁt in MM.
Dose Escalation and Dose Expansion Phases
Patients received ABBV-383 intravenously (IV) over 1-2
hours at a ﬁxed dose once every 3 weeks in the dose escalation phase (Appendix Fig A1, online only). No step or
priming doses were implemented. Patients were premedicated with dexamethasone 10 mg IV (once on day 1) or
equivalent prior to the administration of ABBV-383 for cycle
1. Subsequently, the dose frequency would be prior to the
administration of ABBV-383 only (once every 3 weeks) and it
could be tapered off as stated in the Protocol (online only) for
subsequent cycles. If a patient did not experience an infusion-related reaction or immune-mediated toxicity in a
given cycle, the dexamethasone premedication dose could
be reduced to 5 mg IV (once on day 1) thereafter prior to the
administration of ABBV-383 (once every 3 weeks). If a
patient did not experience an infusion-related reaction or
immune-mediated toxicity in a cycle where they received 5
mg dexamethasone IV (once on day 1) as premedication,
dexamethasone could subsequently be omitted from the
premedication regimen prior to the administration of ABBV383 (once every 3 weeks). Additional administration details
are provided in the Appendix 1 (online only). Fourteen dose
levels were evaluated: 0.025 mg, 0.075 mg, 0.2 mg, 0.6 mg,
1.8 mg, 5.4 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg,
60 mg, 90 mg, and 120 mg. Patients received ABBV-383
until progressive disease (PD), unacceptable toxicity, or up to
3 years after the last patient’s ﬁrst dose.
The study used a 3 1 3 design with backﬁlling for selected
doses and permitted intrapatient escalation to highest safe
dose. In the dose escalation phase, cohorts 1-3 planned to
enroll single patients, and beginning at cohort 4, a standard
3 1 3 dose escalation design was planned. Single-patient
cohorts were planned to be converted to 3 1 3 cohorts if
grade $ 2 toxicity was observed or if deemed appropriate by
the safety monitoring group (eg, medical monitors and principal investigators or designated subinvestigators). Upon
completion of the ﬁrst cycle of the prior dose level, patients
were able to intrapatient dose escalate to the next dose level
following a review of the safety data from the higher dose by the
safety monitoring group. Escalation-dose decisions were based
on clinically signiﬁcant toxicity, dose-limiting toxicity (DLT)
events, and pharmacokinetic (PK) and pharmacodynamic
ﬁndings. DLTs were determined during the ﬁrst 21-day cycle
and deﬁned as a treatment-emergent adverse event (TEAE)
not reasonably attributed to the patient’s underlying disease,
other medical conditions, or concomitant medications or
procedures. The MTD was deﬁned as the highest dose level at
which , two of six evaluable patients experience a DLT.
At the time of the data cutoff, enrollment of the 60 mg
expansion cohort had been completed, and the protocol
was in process of being amended to investigate a lower
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dose (40 mg once every 3 weeks) in an additional expansion cohort (Appendix Fig A1). Patients were allowed to
receive ABBV-383 as long as they did not meet discontinuation criteria or complete the study.
Assessments
Safety was assessed during the study through the evaluation of TEAEs, laboratory proﬁles, physical examinations,
and vital signs. TEAEs were graded according to the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 5.0. TEAEs were captured from the
time of consent until 90 days after discontinuation of ABBV383. Serious TEAEs met the following criteria: death of
patient, life-threatening, involved hospitalization, signiﬁcant
disability/incapacity, or required medical/surgical intervention to prevent serious outcome.
Blood samples for ABBV-383 PK analysis and antidrug
antibody (ADA) analysis were collected at designated time
points throughout the study and analyzed using the validated
assays. PK parameters of ABBV-383 were determined using
noncompartmental methods. Immunogenicity of ABBV-383
was summarized on the basis of the available ADA data.
Efﬁcacy was assessed using 2016 IMWG uniform response
criteria,19 including the objective response rate (ORR; deﬁned as conﬁrmed stringent complete response [sCR] plus
complete response [CR] plus very good partial response
[VGPR] plus partial response [PR]), OS, progression-free
survival (PFS), time-to-progression, time-to-response, and
duration of response (DoR). IMWG laboratory assessments
(serum protein electrophoresis, urine protein electrophoresis, serum and urine immunoﬁxation, serum free light
chains, and serum quantitative immunoglobulins) were
performed by a central laboratory. Imaging assessments
were performed locally. All response categories required two
consecutive assessments for conﬁrmation. Minimal residual
disease (MRD) was assessed by immunoglobulin gene
rearrangement sequencing (Adaptive Biotechnologies,
Seattle, WA) on bone marrow aspirate DNA at the time of
suspected CR/sCR. PFS was deﬁned as the time from the
ﬁrst dose of ABBV-383 to PD or death, whichever occurred
ﬁrst. OS was deﬁned as the time from the ﬁrst dose of ABBV383 to death due to any cause. Patients were censored at the
last known alive date on or before the data cutoff or snapshot
date if no death occurred. Time-to-progression was deﬁned
as the duration from start of treatment to PD. Time-toresponse was deﬁned as the time of start of study treatment to ﬁrst conﬁrmed response ($ PR). The DoR was
deﬁned as the time from the initial objective response to PD
or death, whichever occurred ﬁrst; patients were censored at
the date of last tumor assessment if neither event occurred.
Statistical Analysis
The safety population included all patients who received
$ 1 dose of ABBV-383. The efﬁcacy-evaluable population
was deﬁned as patients who received $ 1 dose of ABBV383 and have $ 1 postdose disease assessment. The PK
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TABLE 1. Patient Characteristics
60 mg EXP (n 5 51)

‡ 40 mg ESC 1 EXP (n 5 81)

All Patients (N 5 124)

Median age, years (range)

68 (35-92)

68 (35-92)

68 (35-92)

Male, No. (%)

26 (51)

44 (54)

68 (55)

40 (78)

63 (78)

98 (79)

Black or African American

7 (14)

13 (16)

20 (16)

Asian

1 (2)

1 (1)

1 (1)

Not reported

3 (6)

4 (5)

5 (4)

Characteristic

Race, No. (%)
White

Ethnicity, No. (%)
Hispanic

2 (4)

3 (4)

5 (4)

49 (96)

78 (96)

119 (96)

0

20 (39)

31 (38)

40 (32)

1

27 (53)

44 (54)

71 (57)

3 (6)

4 (5)

11 (9)

6 (1-15)

6 (1-17)

Not Hispanic or Latino
ECOG PS score,a No. (%)

2
Median time since initial diagnosis to screening, years (range)

7 (0-20)

b

Revised ISS stage at entry, No. (%)
I

9 (18)

14 (17)

19 (15)

II

12 (24)

17 (21)

23 (19)

III

15 (29)

24 (30)

38 (31)

High-risk cytogenetics,c No. (%)

6 (12)

11 (14)

22 (18)

Median prior lines of therapy, No. (range)

4 (3-12)

4 (3-12)

5 (3-15)

Prior MM therapy, No. (%)
Autologous SCT

42 (82)

67 (83)

100 (81)

Anti-CD38 antibody refractory

49 (96)

78 (96)

120 (97)

Double refractoryd

45 (88)

68 (84)

104 (84)

Triple-class exposed

50 (98)

80 (99)

123 (99)

Triple-class refractorye

43 (84)

66 (81)

102 (82)

Penta-class exposed

45 (88)

74 (91)

113 (91)

Penta-class refractoryf

23 (45)

33 (41)

44 (35)

43 (84)

69 (85)

108 (87)

g

Refractory to last prior cancer therapy, No. (%)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ESC, dose escalation; EXP, dose expansion; IMiD, immunomodulatory
drug; ISS, International Staging System; MM, multiple myeloma; PI, proteasome inhibitor; SCT, stem-cell transplant.
a
Data missing in two patients.
b
Unknown: all patients, n 5 44 (35%); $ 40 mg ESC 1 EXP, n 5 26 (32%); 60 mg EXP, n 5 15 (29%).
c
High-risk cytogenetics was deﬁned as the presence of t(4;14), t(14;16), or 17p deletion as detected by ﬂuorescence in situ hybridization analysis of
CD138-enriched bone marrow aspirates performed at screening.
d
Refractory to a PI and an IMiD.
e
Refractory to an IMiD, a PI, and anti-CD38 antibody.
f
Refractory to $ 2 PIs, $ 2 IMiDs, and $ 1 anti-CD38 antibody.
g
Progressive disease on or within 60 days of last treatment regimen.

population included patients who received $ 1 dose of
ABBV-383 and had $ 1 PK sample drawn.
Frequency distributions were used for categorical variables
and appropriate summary statistics (mean, median, and
range) for quantitative/continuous variables. The two-sided
80% exact binomial CIs of the ORR are summarized using
the Clopper-Pearson method together with the best overall

response (CR, PR, stable disease, and PD). The KaplanMeier method was used to estimate PFS, OS, and DoR.
Descriptive statistics for continuous safety variables and
frequencies/percentages for discrete safety variables were
used. The safety population allowed for detection of serious
TEAEs occurring in as few as 21% of patients with 80%
conﬁdence.
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TABLE 2. Patient Disposition
60 mg EXP (n 5 51)

Disposition

‡ 40 mg ESC 1 EXP (n 5 81)

All Patients (N 5 124)

Treatment ongoing, No. (%)

23 (45)

38 (47)

45 (36)

Discontinued treatment, No. (%)

28 (55)

43 (53)

79 (64)

PD

21 (41)

31 (38)

60 (48)

DLT/AE

2 (4)

4 (5)

7 (6)

Physician decision

2 (4)

2 (2)

4 (3)

0

1 (1)

1 (1)

Cancer-related surgery/anticancer therapy
Withdrawal of consent

3 (6)

4 (5)

5 (4)

15 (29)

25 (31)

55 (44)

Death

9 (18)

14 (17)

33 (27)

Withdrawal of consent

3 (6)

8 (10)

15 (12)

Lost to follow-up, No. (%)

0

Discontinued study, No. (%)

Deaths, No. (%)

0

1 (1)

9 (18)

14 (17)

33 (27)

. 30 days from last dose

7 (14)

12 (15)

30 (24)

# 30 days from last dose

2 (4)

2 (2)

3 (2)

. 90 days from last dose

3 (6)

5 (6)

12 (10)

# 90 days from last dose
Median follow-up, months (range)

6 (12)
8.2 (0.6-11.5)

9 (11)
9.6 (0.6-18.2)

21 (17)
10.8 (0.6-28.2)

Abbreviations: AE, adverse event; DLT, dose-limiting toxicity; ESC, dose escalation; EXP, dose expansion; PD, progressive disease.

RESULTS
Patient Demographics and Baseline Characteristics
As of January 8, 2022, 124 patients were enrolled (escalation phase, n 5 73; expansion phase, n 5 51). Demographics and baseline characteristics of treated patients
(N 5 124) are shown in Table 1 and includes patients
treated in the $ 40 mg escalation- plus expansion-phase
cohorts (n 5 81) and 60 mg expansion cohort (n 5 51). In
the overall population, the median age was 68 years (range,
35-92 years), 55% were male, and 57% had an ECOG PS
score of 1. The median number of prior lines of therapy was
5 (range, 3-15 lines), and 87% of patients were refractory to
the last prior therapy. Patient disposition is shown in
Table 2. Treatment is ongoing in 45 (36%) patients, and 79
(64%) patients discontinued treatment, mostly because of
PD (n 5 60/79; 76%). Fifty-ﬁve (44%) patients discontinued study participation; reasons included death
(n 5 33; 27%), withdrawal of consent (n 5 15; 12%), and
lost to follow-up (n 5 1; 1%). Of the 33 (27%) reported
deaths, 30 occurred . 30 days from the last dose of ABBV383 and three occurred # 30 days from the last dose; 12
occurred . 90 days from last ABBV-383 dose and 21
occurred # 90 days from last dose.
Safety
TEAEs (all grades, grade $ 3) in the overall population
(N 5 124), $ 40 mg escalation plus expansion (n 5 81),
and 60 mg expansion cohorts (n 5 51) are shown in Table 3.
The proportion of patients experiencing a TEAE (all grades)
was similar in the overall population (98%), $ 40 mg
3580 © 2022 by American Society of Clinical Oncology

escalation plus expansion (99%), and 60 mg expansion
cohorts (98%); 72%, 77%, and 78%, respectively, experienced a grade $ 3 TEAE. The most common hematologic
TEAEs (all grades [$ 25% total patients]/grade $ 3) in the
overall population were neutropenia (37%/34%) and anemia
(29%/16%); similar results were reported for the $ 40 mg
escalation plus expansion and 60 mg expansion cohorts.
The most common nonhematologic TEAEs (all grades
[$ 25% total patients]) in the overall population were CRS
(57%), fatigue (30%), nausea (29%), and diarrhea (27%);
and in the $ 40 mg escalation plus expansion/60 mg expansion (all grades [$ 30% of patients]) were CRS (73%/
71%), nausea (35%/31%), diarrhea (32%/29%), and fatigue (30%/29%). Hypogammaglobulinemia occurred in 17
(14%) patients in the overall population. Twenty-nine (23%)
patients in the overall population required administration of
immunoglobulins (intravenous, n 5 15 [12%]; not otherwise
speciﬁed, n 5 14 [11%]; preferred terms have the potential
for overlapping).
In the overall population, serious TEAEs occurred in 66
(53%) patients, of whom 48 (59%) patients received
$ 40 mg doses of ABBV-383 (escalation plus expansion
cohorts, n 5 81) and 31 (61%) patients received 60 mg
(expansion cohort, n 5 51). TEAEs of infection occurred in
51 (41%) patients overall ($ 40 mg escalation plus expansion cohorts: n 5 36/51, 44%; 60 mg expansion cohort:
n 5 24/51, 47%); 31 (25%) patients reported serious
events. Grade $ 3 events of infections ($ 5% total patients)
in the overall population were pneumonia, sepsis, COVID19 disease (6% each), and urinary tract infections (5%).
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TABLE 3. TEAEs
TEAE

60 mg EXP (n 5 51)

‡ 40 mg ESC 1 EXP (n 5 81)

All Patients (N 5 124a)

3 (6)

6 (7)

12 (10)

20 (39)

36 (44)

46 (37)

4 (8)

6 (7)

6 (5)

0

3 (4)

3 (2)

1 (2)

4 (5)

7 (6)

Leading to study drug discontinuation, No. (%)
Leading to study drug interruption, No. (%)
Leading to dose reduction, No. (%)
Associated with DLT, No. (%)
Leading to death, No. (%)

TEAEs (any grade) Occurring in
‡ 15% of Total Patients

All Grades

Grade ‡ 3

All Grades

Grade ‡ 3

All Grades

Grade ‡ 3

50 (98)

40 (78)

80 (99)

62 (77)

121 (98)

89 (72)

Neutropeniab

21 (41)

18 (35)

37 (46)

33 (41)

46 (37)

42 (34)

Anemia

17 (33)

7 (14)

28 (35)

14 (17)

36 (29)

20 (16)

Thrombocytopeniac

13 (25)

5 (10)

20 (25)

9 (11)

29 (23)

15 (12)

11 (22)

10 (20)

16 (20)

13 (16)

19 (15)

16 (13)

CRS

36 (71)

1 (2)

59 (73)

3 (4)

71 (57)

3 (2)

Fatigue

15 (29)

0

24 (30)

0

37 (30)

1 (1)

Nausea

16 (31)

0

28 (35)

2 (2)

36 (29)

2 (2)

Diarrhea

15 (29)

1 (2)

26 (32)

1 (1)

34 (27)

2 (2)

Vomiting

10 (20)

0

23 (28)

0

30 (24)

0

Pyrexia

11 (22)

0

17 (21)

0

24 (19)

0

6 (12)

0

12 (15)

0

22 (18)

0

Any, No. (%)
Hematologic, No. (%)

d

Lymphopenia

Nonhematologic, No. (%)

Arthralgia
Cough

11 (22)

0

16 (20)

0

20 (16)

0

Headache

4 (8)

0

10 (12)

1 (1)

20 (16)

2 (2)

Pain in extremity

8 (16)

0

14 (17)

0

20 (16)

0

Abbreviations: AE, adverse event; CRS, cytokine release syndrome; DLT, dose-limiting toxicity; ESC, dose escalation; EXP, dose expansion; TEAE,
treatment-emergent adverse event.
a
Safety population deﬁned as patients who have received $ 1 dose of ABBV-383.
b
Neutropenia includes neutropenia, neutrophil count decreased, and febrile neutropenia.
c
Thrombocytopenia includes platelet count decrease.
d
Lymphopenia includes lymphocyte count decrease.

TABLE 4. CRS: Rate and Grade
60 mg EXP (n 5 51)

‡ 40 mg ESC 1 EXP (n 5 81)

All Patients (N 5 124)

All grades, No. (%)

36 (71)

59 (73)

71 (57)

Grade 1, No. (%)

25 (49)

38 (47)

44 (35)

Grade 2, No. (%)

10 (20)

18 (22)

24 (19)

CRS

Grade $ 3, No. (%)
Serious, No. (%)

1 (2)

3 (4)

3 (2)

15 (29)

21 (26)

22 (18)

Median time to onset, days (range)

1 (1-2)

1 (1-2)

1 (1-7)

Median time to resolution, days (range)

1 (1-8)

1 (1-8)

1 (1-8)

1 (1)

1 (1)

Recurrent CRS after cycle 1, No. (%)

0

NOTE. Severity of the CRS is uniformly graded according to NCI CTCAE v5.0. Grade $ 3 events include one patient from the dose escalation cohort 14
(120mg once every 3 weeks) with initially reported severity of CRS as grade 3 because of transient organ toxicity in addition to pyrexia with absence of
hypotension or hypoxia. This CRS event was subsequently adjudicated by the investigator to grade 1 severity to align with the CRS grading by NCI CTCAE v5.0.
Abbreviations: CRS, cytokine release syndrome; ESC, dose escalation; EXP, dose expansion; NCI CTCAE, National Cancer Institute Common Terminology
Criteria for Adverse Events.
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TABLE 5. Response Rates by IMWG Criteria
‡ 40 mg ESC 1 EXP
(n 5 79)

Triple-Class Refractorya (‡ 40 mg
ESC 1 EXP) (n 5 64)

60 mg EXP
(n 5 49)

ORR, No. (%)

54 (68)

40 (63)

29 (59)b

22 (54)

69 (57)

$ VGPR, No. (%)

43 (54)

33 (52)

19 (39)

15 (37)

52 (43)

sCR

16 (20)

12 (19)

4 (8)

3 (7)

21 (17)

CR

13 (16)

12 (19)

7 (14)

7 (17)

14 (11)

VGPR

14 (18)

9 (14)

8 (16)

5 (12)

17 (14)

PR

11 (14)

7 (11)

10 (20)

7 (17)

17 (14)

Overview of Efﬁcacy

Triple-Class Refractorya
(60 mg EXP) (n 5 41)

Total
(N 5 122)

Best overall response, No. (%)

MR

1 (1)

1 (2)

1 (2)

1 (2)

2 (2)

SDc

18 (23)

17 (27)

14 (29)

13 (32)

36 (30)

PD

6 (8)

6 (9)

5 (10)

5 (12)

15 (12)

Abbreviations: CR, complete response; ESC, dose escalation; EXP, dose expansion; IMWG, International Myeloma Working Group; MR, minor response;
ORR, objective response rate; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial
response; $ VGPR, VGPR or better.
a
Refractory to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody; programmatically derived conﬁrmed or unconﬁrmed
response (IMWG 2016).
b
Total values because of rounding.
c
Inclusive of unconﬁrmed VGPR (2 out of 36 patients) and unconﬁrmed PD (8 out of 36 patients).

In the overall population, TEAEs leading to discontinuation,
interruption, or dose reduction of ABBV-383 occurred in 12
(10%), 46 (37%), and six (5%) patients, respectively;
neutrophil count decrease was the most common TEAE
(n 5 15; 12%) leading to interruption of ABBV-383, and
CRS was the most common TEAE (n 5 3; 2%) leading to
dose reduction. Three patients experienced DLTs (DLT
population: N 5 73), all within the escalation cohorts
(platelet count decreased [grade 4; 60 mg] and CRS [grade
3; 90 mg and 120 mg]). The MTD for ABBV-383 was not
reached during the dose escalation phase, and doseexpansion was initiated with the 60 mg dose of ABBV383 once every 3 weeks on the basis of CRS, plateauing
ORR, and PK.
TEAEs leading to death occurred in seven (6%) patients
due to COVID-19 disease (n 5 3; 0.025 mg, 0.2 mg, and 60
mg), sepsis (n 5 1; 5.4 mg), liver injury (n 5 1; 50 mg),
subdural hematoma (n 5 1; 90 mg), and plasma cell
myeloma (n 5 1; 60 mg expansion cohort). All deaths were
considered to be unrelated to ABBV-383 by the
investigator.
Overview: AE of Interest
Details of CRS are shown in Table 4 and Appendix
Figure A2 (online only). All events of CRS were considered
to be related to ABBV-383 by the investigator. The onset of
CRS typically occurred on the same day or the day following
the ﬁrst dose of ABBV-383, with a median time to onset of
1 day (overall population: range, 1-7 days; $ 40 mg escalation plus expansion cohorts: range, 1-2 days). The
median time to resolution was 1 day (range, 1-8 days) in both
the overall population and $ 40 mg escalation plus expansion cohorts; patients recovered quickly with standard

3582 © 2022 by American Society of Clinical Oncology

supportive care measures and/or administration of tocilizumab. Most CRS events were grade 1 or 2 in all dose groups
(Table 4). CRS grade $ 3 occurred in three (3%) patients at
doses $ 60 mg (one each at 60 mg [expansion], and 90 mg
and 120 mg [escalation]). Serious CRS events occurred in
22 (18%) patients in the overall population, 21 (26%) of
which were in the $ 40 mg escalation plus expansion cohorts. A single patient in the study (at 40 mg) experienced
recurrent CRS after cycle 1 (ﬁrst event: grade 1, cycle 1 day
1-3; recurrent event: day 70 [cycle 4], 40 mg dose level). In
total, 17 (14%) patients, all within the $ 40 mg escalation
plus expansion cohorts, received tocilizumab.
Serious TEAEs considered to be neurotoxic, as evidenced
by the preferred term immune effector cell-associated
neurotoxicity, were reported in two patients (60 mg each).
PK and Immunogenicity
The preliminary PK analysis included data from 99 patients.
ABBV-383 demonstrated dose-proportional PK at doses
between 5.4 mg and 120 mg (Appendix Fig A3, online
only). ABBV-383 concentrations from 0.025 mg and
0.075 mg were below the limits of quantiﬁcation. The halflife (t1/2) was approximately 12 days for doses between
5.4 mg and 120 mg, supporting the once every 3 weeks
dosing schedule. Preliminary immunogenicity assessment
of ABBV-383 indicates a relatively low incidence of immunogenicity with only four out of 76 (5%) evaluable patients treated with ABBV-383 having low-titer ADAs.
Efﬁcacy
Response rates by dose group are shown in Table 5. The
ORR and VGPR or better ($ VGPR) rates for all efﬁcacyevaluable patients (n 5 122) were 57% and 43%,
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A
Censored

PFS (probability)

1.0
PFS

60 mg (EXP)
(n = 51)

≥ 40 mg (ESC + EXP)
(n = 81)

All Patients
(N = 124)

0.7

Median, months (range)

NR (4.7-NR)

NR (6.3-NR)

10.4 (5.0-19.2)

0.6

KM estimate, % (95% CI)
6 months
12 months

60.8 (43.6 to 74.2)
57.0 (39.4 to 71.3)

63.5 (50.4 to 74.0)
57.9 (44.6 to 69.1)

57.5 (47.3 to 66.4)
46.6 (35.9 to 56.6)

DoR

60 mg (EXP)
(n = 29)

≥ 40 mg (ESC + EXP)
(n = 54)

All Patients
(N = 69)

Median, months (range)

NR (NR)

NR (12.9-NR)

NR (12.9-NR)

KM estimate, % (95% CI)
6 months
12 months

79.9 (53.8 to 92.2)
79.9 (53.8 to 92.2)

74.8 (59.0 to 85.2)
72.2 (56.1 to 83.2)

76.3 (63.2 to 85.3)
67.2 (52.6 to 78.2)

0.9
0.8

0.5
0.4
0.3

All patients (N = 124)

0.2

95% CI LL for PFS

0.1

95% CI UL for PFS

0.0
0.0 1.5 3.0 4.5 6.0 7.5 9.0 10.5 12.0 13.5 15.0 16.5 18.0 19.5 21.0 22.5 24.0

Time Since First Dose (months)
No. at risk:
All patients

124

97

80

60

53

43

37

28

25

22

17

13

8

1

1

1

0

Probability of Continuing Response

B
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1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3

All patients (N = 124)

0.2

95% CI LL for PFS

0.1

95% CI UL for PFS

0.0
0.0

1.5

3.0

4.5

6.0

7.5

9.0 10.5 12.0 13.5 15.0 16.5 18.0 19.5 21.0 22.5

Time Since First Dose (months)
No. at risk:
All patients

69

67

57

49

41

38

31

23

19

14

12

9

4

1

1

0

FIG 1. DoR by IMWG criteria and PFS. DoR is for $ PR. DoR, duration of response; ESC, dose escalation; EXP, dose expansion; IMWG, International
Myeloma Working Group; KM, Kaplan-Meier; LL, lower limit; NR, not reached; PFS, progression-free survival; UL, upper limit.

respectively. In the 60 mg expansion cohort (n 5 49), the
ORR and $ VGPR rates were 59% and 39%, respectively;
and in the $ 40 mg escalation plus expansion cohorts
(n 5 79) were 68% and 54%, respectively. Of the 11 MRDevaluable patients with CR or sCR, eight (73%) were MRDnegative (# 10–5). All ﬁve MRD-evaluable patients treated
in the $ 40 mg escalation plus expansion cohorts achieved
MRD-negative CR at # 10–6 sensitivity threshold by nextgeneration sequencing. In triple-class refractory patients
(deﬁned as refractory to an IMiD, a PI, and an anti-CD38
mAb) overall (n 5 100), the $ 40 mg escalation plus
expansion cohorts (n 5 64), and 60 mg expansion cohort
(n 5 41), the ORRs were 51%, 63%, and 54%, respectively. In patients with high-risk cytogenetics in the $ 40 mg
escalation plus expansion cohorts (n 5 11), the ORR, $ CR
(sCR), VGPR, and PR rates were 82%, 27% (18%), 73%,
and 9%, respectively. DoR for patients who achieved $ PR
(n 5 69) is shown in Figure 1A. At the time of the data
cutoff, the median DoR had not been reached in the 60 mg
expansion (n 5 29) or the $ 40 mg escalation plus expansion cohorts (n 5 54). The Kaplan-Meier estimate for
the 6- and 12-month DoR rate was 79.9% (95% CI, 53.8 to
92.2) and 79.9% (95% CI, 53.8 to 92.2), respectively, for
the 60 mg expansion cohort, and 74.8% (95% CI, 59.0 to

85.2) and 72.2% (95% CI, 56.1 to 83.2), respectively, for
the $ 40 mg escalation plus expansion cohorts. Response
over time for patients who achieved $ PR (n 5 69) is shown
in Appendix Figure A4 (online only). Median PFS was not
reached in the $ 40 mg escalation plus expansion (n 5 81)
and 60 mg expansion (n 5 51) cohorts (Fig 1B), and was
10.4 months (range, 5-19.2 months) on the overall population (N 5 124). Overall, the median duration of follow-up
was 10.8 months (range, 0.6-28.2 months) for all treated
patients (N 5 124), 8.2 months (range, 0.6-11.5 months)
in the 60 mg expansion cohort (n 5 51), and 9.6 months
(range, 0.6-18.2 months) in the $ 40 mg escalation plus
expansion cohorts (n 5 81; Table 2).
DISCUSSION
The results of this ﬁrst-in-human, phase I study in patients
with RRMM demonstrated that the T-BsAb BCMA-targeted
therapy ABBV-383 was well tolerated at all doses administered, with a low incidence of grade $ 3 hematologic and
nonhematologic TEAEs. ABBV-383 was associated with
predictable and manageable CRS, without the need to
implement step-dosing, and resolution occurred quickly
with standard supportive care measures including the
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administration of tocilizumab if needed; only 14% of patients received tocilizumab. The majority of CRS events
were grade 1 or 2 and resolved in 1 day. PK data indicated a
t½ of approximately 12 days, supporting the extended once
every 3 weeks dosing. ABBV-383 also demonstrated a low
level of immunogenicity, with ADA formation reported in
only 5% of patients. In addition, ABBV-383 showed
promising efﬁcacy in the treatment of RRMM with an ORR
of 59% observed at 60 mg in the expansion cohort (median
follow-up: 8.2 months) and an ORR of 68% observed in
the $ 40 mg escalation plus expansion cohorts (with a
longer median follow-up of 9.6 months). The median 6- and
12-month DoR estimates were . 72% for both the 60 mg
expansion cohort and the $ 40 mg escalation plus expansion cohort. The MTD was not reached, and the 60 mg
once every 3 weeks dose was selected for dose-expansion
on the basis of CRS, plateauing ORR, and PK.
BCMA is an important target for the treatment of RRMM,
and several BCMA-targeted therapies have been approved
or are in clinical development. These include belantamab
mafodotin, CAR-T therapies (eg, idecabtagene vicleucel,
and ciltacabtagene autoleucel), as well as the BsAbs CC93269, REGN5458, teclistamab, and elranatamab. ABBV383 has similar or improved efﬁcacy in terms of ORRs (59%
[60 mg expansion] and 68% [$ 40 mg escalation plus
expansion]) compared with the ADC belantamab mafodotin
(32%),20 the CAR-T therapies (61.5%-97%),21-24 and the

aforementioned BsAbs (44%-75%).25-28 The tolerability
proﬁle of ABBV-383 demonstrated a 57% overall incidence
of CRS (73% at $ 40 mg) without implementation of
priming. CAR-T therapies have reported the following CRS
rates: idecabtagene vicleucel, 84%24; ciltacabtagene
autoleucel, 95%.22 For BsAbs, overall CRS rate is approximately 70 (eg, CC-93269, 77%26; teclistamab, 72%27;
elranatamab, 73%25), which includes lower doses. In addition, this study allowed for the inclusion of patients with
diminished renal function as well as patients who received
allogenic transplant in comparison with CAR-T therapy
clinical studies. The once every 3 weeks schedule of ABBV383 was also viewed as convenient in that it may lead to
improved compliance from patients as well as minimize the
use of hospital resources. Finally, ABBV-383 has off-theshelf availability, unlike CAR-T therapies, as well as shorter
hospitalization time (ﬁrst 48 hours after initial administration) versus other BCMAs and CAR-T therapies.
Limitations of this study involve the small number of patients enrolled in the dose escalation cohorts. Efforts are
ongoing to determine the optimal dose regimen for ABBV383 with lower doses being explored. ABBV-383 doses of
60 mg once every 3 weeks as well as 40 mg once every
3 weeks have been selected for further dose exploration
and optimal-dose selection. The safety and efﬁcacy of
ABBV-383 will be investigated further in this ongoing phase
I study.
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APPENDIX 1. METHODS
Study Treatment
ABBV-383 is administered by intravenous (IV) infusion over 1-2 hours at
a ﬁxed dose once every 3 weeks. If no infusion reactions occur during the
ﬁrst dose, the duration of the infusion for subsequent doses can be
reduced to 1 hour. ABBV-383 cannot be administered over a period ,
1 hour. Patients are also routinely premedicated with diphenhydramine

25-50 mg IV (once on day 1) or equivalent, oral acetaminophen
650-1,000 mg (once on day 1), and ranitidine 150 mg oral/IV (once on
day 1) or equivalent, 15-60 minutes before the ABBV-383 infusion (once
every 3 weeks) to reduce the risk and severity of hypersensitivity reactions commonly observed with monoclonal antibody therapy. Patients
can also be premedicated with tocilizumab 8 mg/kg IV (once on day 1) at
the discretion of the investigator or according to the institution’s
guidelines prior to the administration of ABBV-383 (once every 3 weeks).
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TABLE A1. Eligibility Criteria
Key inclusion criteria:
Age $ 18 years
$ three prior lines of therapy with exposure to a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody (ie, daratumumab)
Must not be candidates for treatment regimens known to provide clinical beneﬁt in MM
Note: the number of prior lines of therapy will be determined according to the guidelines provided in the study by Rajkumar et al.29 There is no maximum
number of prior lines of therapy
ECOG PS score of # 2
Adequate bone marrow function (ANC $ 1,000/mm3, platelets $ 50,000/mm3, hemoglobin $ 8.0 g/dL)
Transfusion and/or growth factor support is permitted before assessment, but neutrophils, platelets, and hemoglobin must be stable for at least 72 hours after
transfusion and/or growth factor administration before screening for the patient to be eligible
eGFR $ 30 mL/minute as estimated by the Modiﬁcation of Diet in Renal Disease formula
Total bilirubin # 1.5 3 ULN (excluding a known diagnosis of Gilbert’s syndrome, in which case bilirubin must be , 3 3 ULN) and AST and ALT # 3 3 ULN
Serum calcium (corrected for albumin) at or below the ULN range (patient may enroll in the setting of hypercalcemia at screening IF hypercalcemia resolves with
standard treatment by cycle 1 day 1) before study therapy initiation
Corrected serum calcium (mg/dL) 5 measured serum calcium (mg/dL) 1 0.8 3 (4.0 – serum albumin [g/dL])
Measurable disease as deﬁned by $ 1 of the following:
Serum M-protein $ 0.5 g/dL ($ 5 g/L)
Urine M-protein $ 200 mg/24 hours
Serum FLC assay: involved FLC level $ 10 mg/dL ($ 100 mg/L) and an abnormal serum FLC ratio (, 0.26 or . 1.65)
Conﬁrmed evidence of relapse/progression from the immediately prior MM therapy, or patient is relapsed/refractory to the immediately prior MM therapy
Patient consents to a fresh pretreatment bone marrow tumor biopsy or has adequate archival bone marrow tumor tissue that was collected within 6 months before
screening and without intervening treatment
Key exclusion criteria:
Diagnosed or treated for another malignancy within # 3 years of enrollment (excluding basal cell or squamous cell carcinoma of the skin, in situ malignancy,
low-risk prostate carcinoma after curative therapy, or complete resection/curative therapy of an advanced malignancy)
History of CNS involvement by their myeloma, grade $ 3 peripheral neuropathy, plasma cell leukemia, POEMS syndrome, or amyloidosis
Received another investigational drug # 21 days of enrollment
Received BCMA-targeted therapy (non-BCMA targets were not excluded)
Received an autologous stem-cell transplant (# 12 weeks) or an allogeneic stem-cell transplant (# 1 year) before ﬁrst dose of study drug treatment
Received any therapy to treat cancer (including radiation, chemotherapy, biologics, cellular therapies, and/or steroids at doses . 20 mg dexamethasone or
equivalent) or undergone a major surgical procedure # 21 days, or within 5 half-lives of an anticancer drug, before the ﬁrst dose of study treatment, whichever is
shorter
Known active infection grade $ 2 requiring anti-infective treatment. Upon completion of anti-infectives and resolution to grade # 1, the patient is considered
eligible for the study from an infection standpoint. For patients who have active SARS-CoV-2 infection:
If the subject has signs/symptoms suggestive of SARS-CoV-2 infection, he/she should undergo molecular (eg, polymerase chain reaction) testing to conﬁrm
SARS-CoV-2 infection. Patients who meet SARS-CoV-2 infection criteria must be screen failed but will be allowed to rescreen
Conﬁrmed positive test results for HIV, or patients with chronic or active infection with HBV or HCV
Patients who have a history of HBV or HCV who have documented cures (HBV: hepatitis B surface antigen–negative; HCV: undetectable HCV ribonucleic acid
24 weeks after the EOT) may enroll
Major cardiac abnormalities such as, but not limited to, the following: uncontrolled angina or unstable life-threatening arrhythmias, history of myocardial infarction
# 12 weeks before screening, class $ 3 New York Heart Association congestive heart failure, severe cardiac insufﬁciency, or persistent QTc prolongation (. 480
ms, QTc per Fridericia’s formula)
Unresolved AEs $ grade 2 (NCI CTCAE, version 5.0) from prior anticancer therapy except for:
Alopecia
Peripheral neuropathy ($ grade 3 will be excluded)
Anemia or thrombocytopenia (anemia must be grade 3, and thrombocytopenia must be grade 4 to trigger exclusion, grade 3 with symptoms or bleeding,
respectively, or return within 72 hours despite transfusion support)
Irreversible toxicity not reasonably expected to be exacerbated by any of the investigational products may be included (eg, hearing loss) after consultation with
the study medical monitor

Abbreviations: ANC, absolute neutrophil count; BCMA, B-cell maturation antigen; ECOG PS, Eastern Cooperative Oncology Group
performance status; eGFR, estimated glomerular ﬁltration rate; EOT, end-of-treatment; FLC, free light chain; HBV, hepatitis B virus; HCV,
hepatitis C virus; HIV, human immunodeﬁciency virus; MM, multiple myeloma; NCI CTCAE, National Cancer Institute Common Terminology
Criteria for Adverse Events; POEMS, polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes; QTc, QT interval
corrected for heart rate; ULN, upper limit of normal.
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